Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
NCT00000602 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2016-09-16
Summary
To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.
Conditions
- Anemia, Sickle Cell
- Hematologic Diseases
- Hemoglobinopathies
Interventions
- DRUG
-
hydroxyurea
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 1 Year
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1994-04-30
- Completion
- 1997-03-31
More Related Trials
-
Hydroxyurea and Transfusion
NCT03644953 ·Status: COMPLETED ·Phase: PHASE2
-
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
NCT01506544 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
NCT02225132 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Realizing Effectiveness Across Continents With Hydroxyurea
NCT06171217 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Hydroxyurea in Young Children With Sickle Cell Anemia
NCT00519701 ·Status: COMPLETED ·Phase: NA
-
Novel Dose Escalation to Predict Treatment With Hydroxyurea
NCT02042222 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
NCT05681598 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Response Evaluation and Adherence Trial (TREAT)
NCT02286154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175 ·Status: COMPLETED
-
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
NCT05285917 ·Status: RECRUITING ·Phase: PHASE3
-
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
NCT01389024 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
NCT00000586 ·Status: COMPLETED ·Phase: PHASE3
-
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
NCT00270478 ·Status: COMPLETED ·Phase: PHASE1
-
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
NCT02149537 ·Status: COMPLETED ·Phase: PHASE4
-
Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease
NCT00784082 ·Status: COMPLETED
-
Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
NCT01966731 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
NCT06761560 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
NCT00532883 ·Status: TERMINATED ·Phase: PHASE2
-
Shared-Decision Making for Hydroxyurea
NCT03442114 ·Status: COMPLETED ·Phase: NA
-
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
NCT00402480 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Use Of Hydroxyurea in an African Region With Malaria
NCT01976416 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Hydroxyurea to Treat Sickle Cell Disease
NCT02868138 ·Status: COMPLETED
-
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease
NCT00495638 ·Status: COMPLETED
-
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
NCT07177300 ·Status: RECRUITING ·Phase: PHASE4